Misako Nakata

Sucampo Pharma LLC engages in the pharmaceutical product development. It develops the naturally occurring compound prostones, including lubiprostone under the brand Amitiza, which is used for the treatment of chronic constipation, chronic idiopathic constipation (CIC) in adults, and irritable bowel syndrome with constipation (IBS-C). The company is headquartered in Osaka, Japan.

VLP Therapeutics LLC operates as a biopharmaceutical company. The firm focuses on developing preventative and therapeutic vaccines, as well as next generation targeted antibody agents to treat cancer and infectious diseases, such as malaria, dengue fever, zika virus-based diseases, and autoimmune. The company was founded by Wataru Akahata, Ryuji Ueno, Sachiko Kuno, Kei S. Tolliver and Misako Nakata in 2012 and is headquartered in Gaithersburg, MD.

VLP Therapeutics LLC operates as a biopharmaceutical company. The firm focuses on developing preventative and therapeutic vaccines, as well as next generation targeted antibody agents to treat cancer and infectious diseases, such as malaria, dengue fever, zika virus-based diseases, and autoimmune. The company was founded by Wataru Akahata, Ryuji Ueno, Sachiko Kuno, Kei S. Tolliver and Misako Nakata in 2012 and is headquartered in Gaithersburg, MD.

Sucampo Pharma LLC engages in the pharmaceutical product development. It develops the naturally occurring compound prostones, including lubiprostone under the brand Amitiza, which is used for the treatment of chronic constipation, chronic idiopathic constipation (CIC) in adults, and irritable bowel syndrome with constipation (IBS-C). The company is headquartered in Osaka, Japan.

VLP Therapeutics LLC operates as a biopharmaceutical company. The firm focuses on developing preventative and therapeutic vaccines, as well as next generation targeted antibody agents to treat cancer and infectious diseases, such as malaria, dengue fever, zika virus-based diseases, and autoimmune. The company was founded by Wataru Akahata, Ryuji Ueno, Sachiko Kuno, Kei S. Tolliver and Misako Nakata in 2012 and is headquartered in Gaithersburg, MD.

VLP Therapeutics LLC operates as a biopharmaceutical company. The firm focuses on developing preventative and therapeutic vaccines, as well as next generation targeted antibody agents to treat cancer and infectious diseases, such as malaria, dengue fever, zika virus-based diseases, and autoimmune. The company was founded by Wataru Akahata, Ryuji Ueno, Sachiko Kuno, Kei S. Tolliver and Misako Nakata in 2012 and is headquartered in Gaithersburg, MD.